Orphan drug designation for novel drug selinexor as a treatment for myeloma

The US pharmaceutical company, Karyopharm Therapeutics Inc., has announced that the FDA has granted orphan drug designation for its lead drug candidate, selinexor (KPT-330), as a treatment for myeloma. This follows similar orphan drug designation granted recently by the European Medicines Agency (EMA). Selinexor is a first-in-class oral selective inhibitor of nuclear export which acts…

Details